JP2023530271A - Apol1の阻害剤及びこれを使用する方法 - Google Patents

Apol1の阻害剤及びこれを使用する方法 Download PDF

Info

Publication number
JP2023530271A
JP2023530271A JP2022575989A JP2022575989A JP2023530271A JP 2023530271 A JP2023530271 A JP 2023530271A JP 2022575989 A JP2022575989 A JP 2022575989A JP 2022575989 A JP2022575989 A JP 2022575989A JP 2023530271 A JP2023530271 A JP 2023530271A
Authority
JP
Japan
Prior art keywords
groups
branched
optionally substituted
hydroxy
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530271A5 (cg-RX-API-DMAC7.html
Inventor
ジンロン ツァオ,
ジョン エイチ. カム,
レスリー エー. デーキン,
フランソワ デニス,
ウォーレン エー. ドルシュ,
アン フォティア,
マーティン ハメル,
エレイン ビー. クルーガー,
ブライアン レッドフォード,
フランソワ マルタイス,
スガンティニ エス. ナンタクマール,
オリビエ ニコラス,
カミール イー. セイエグ,
ティモシー ジェイ. センター,
ティアンシェン ワン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2023530271A publication Critical patent/JP2023530271A/ja
Publication of JP2023530271A5 publication Critical patent/JP2023530271A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2022575989A 2020-06-12 2021-06-11 Apol1の阻害剤及びこれを使用する方法 Pending JP2023530271A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038275P 2020-06-12 2020-06-12
US63/038,275 2020-06-12
US202063040183P 2020-06-17 2020-06-17
US63/040,183 2020-06-17
PCT/US2021/036954 WO2021252859A1 (en) 2020-06-12 2021-06-11 Inhibitors of apol1 and use of the same

Publications (2)

Publication Number Publication Date
JP2023530271A true JP2023530271A (ja) 2023-07-14
JP2023530271A5 JP2023530271A5 (cg-RX-API-DMAC7.html) 2024-06-06

Family

ID=76731125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575989A Pending JP2023530271A (ja) 2020-06-12 2021-06-11 Apol1の阻害剤及びこれを使用する方法

Country Status (7)

Country Link
US (1) US12281102B2 (cg-RX-API-DMAC7.html)
EP (1) EP4165022A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530271A (cg-RX-API-DMAC7.html)
CN (1) CN116157393A (cg-RX-API-DMAC7.html)
AU (1) AU2021286728A1 (cg-RX-API-DMAC7.html)
CA (1) CA3185604A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021252859A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503737A (ja) * 2022-01-18 2025-02-04 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法
JP7909027B2 (ja) 2022-01-18 2026-08-20 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2026078446A2 (en) * 2024-10-08 2026-04-16 Brandaris Therapeutics B.V. 5,6-bicyclic 5-ht2ar agonists and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266763B (de) * 1965-07-27 1968-04-25 Kalle Ag Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
CN106008477A (zh) * 2016-06-02 2016-10-12 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法
JP7573528B2 (ja) * 2018-12-17 2024-10-25 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びその使用方法
JP7668804B2 (ja) * 2020-01-29 2025-04-25 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤およびこれを使用する方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0924209B1 (en) 1997-12-19 2003-05-02 Eli Lilly And Company Hypoglycemic imidazoline compounds
GB9816263D0 (en) * 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2002028831A1 (en) 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
AU2004268919A1 (en) 2003-09-03 2005-03-10 Galapagos Nv Novel 4-piperidinecarboxamide and the use thereof for the preparation of medicaments against 5-HT2A receptor-related disorders
WO2005092854A1 (en) 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
WO2007061763A2 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2178870B1 (en) 2007-08-17 2018-09-19 LG Chem, Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
BR112017007178A2 (pt) 2014-10-08 2017-12-19 Ass Francaise Contre Les Myopathies compostos de aminopiridina úteis como inibidores de prenilação de proteína
HRP20210472T1 (hr) 2015-08-27 2021-05-14 Pfizer Inc. Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
CN118127019A (zh) 2018-05-22 2024-06-04 Ionis制药公司 Apol1表达的调节剂
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
EP4114385A1 (en) 2020-03-06 2023-01-11 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
US20230014907A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
KR20240051990A (ko) 2021-08-26 2024-04-22 버텍스 파마슈티칼스 인코포레이티드 스피로트리시클릭 apol1 억제제의 고형분 형태 및 이의 사용 방법
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2022401847A1 (en) 2021-11-30 2024-06-06 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023154314A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Spiro piperidine derivatives as inhibitors of apol1 and methods of using same
EP4476199A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1266763B (de) * 1965-07-27 1968-04-25 Kalle Ag Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
CN106008477A (zh) * 2016-06-02 2016-10-12 苏州大学 3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法
JP7573528B2 (ja) * 2018-12-17 2024-10-25 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びその使用方法
JP7668804B2 (ja) * 2020-01-29 2025-04-25 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤およびこれを使用する方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503737A (ja) * 2022-01-18 2025-02-04 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法
JP7909027B2 (ja) 2022-01-18 2026-08-20 メイズ セラピューティクス, インコーポレイテッド Apol1阻害剤及び使用方法

Also Published As

Publication number Publication date
CN116157393A (zh) 2023-05-23
AU2021286728A1 (en) 2023-01-19
WO2021252859A1 (en) 2021-12-16
CA3185604A1 (en) 2021-12-16
US20230011118A1 (en) 2023-01-12
EP4165022A1 (en) 2023-04-19
US12281102B2 (en) 2025-04-22

Similar Documents

Publication Publication Date Title
JP7668804B2 (ja) Apol1の阻害剤およびこれを使用する方法
US12281102B2 (en) Inhibitors of APOL1 and methods of using same
US20250042878A1 (en) Inhibitors of apol1 and methods of using same
JP2023529216A (ja) Apol1の阻害剤及びその使用
KR101458007B1 (ko) 사이클로프로판 화합물
CN102229605B (zh) 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
JP2021036004A (ja) Retの阻害剤
JP2022511572A (ja) Il-17調節剤としてのベンズイミダゾロン誘導体及びその類似体
AU2017305399A1 (en) Symmetric or semi-symmetric compounds useful as immunomodulators
CN104684915A (zh) 新型双环衍生物
AU1382500A (en) Pyrrolidine derivatives-ccr-3 receptor antagonists
AU2022217353B2 (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
KR20140040774A (ko) 이미다조피리딘 화합물
JP2016535042A (ja) 2−ベンジル−ベンゾイミダゾール補体因子b阻害剤およびその使用
JP2023520207A (ja) アルファ1-アンチトリプシンのモジュレーター
US6710064B2 (en) Hydantoin compounds useful as anti-inflammatory agents
AU2023254866A1 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
CN114127054B (zh) 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物
JP2022551156A (ja) 疼痛に対する多様な活性を有するホモピペラジニル及びホモピペリジニルキナゾリン-4(3h)-オン誘導体
MXPA04012345A (es) Derivados de pirimidina 2,5-substituida como antagonistas ix del receptor ccr-3.
CN118724900A (zh) 4-氨基-7-氮杂吲哚类化合物、其制备方法及应用
TW201307300A (zh) 趨代謝性麩胺酸受體調節劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251114